George Yancopoulos, co-founder and chief scientific officer of Regeneron Pharmaceuticals Inc REGN, has voiced concerns that the popular GLP-1s class of weight-loss drugs may lead to unintended health risks, particularly rapid muscle loss.

Regeneron Pharmaceuticals Inc REGN的聯(lián)合創(chuàng)始人兼首席科學官喬治·揚科波洛斯（GeorgeYancopoulos）表示擔心，廣受歡迎的GLP-1s類減肥藥可能會導致意外的健康風險，尤其是快速的肌肉損失。

Yancopoulos warned that unless this side effect is mitigated, these treatments could ultimately cause “more harm than good.” Clinical studies indicate that patients using GLP-1s, such as Novo Nordisk A/S’ NVO Ozempic and Wegovy, experience muscle loss much faster than those who lose weight through diet and exercise..

Yancopoulos警告說，除非減輕這種副作用，否則這些治療最終可能導致“弊大于利”。臨床研究表明，使用GLP-1s的患者，如諾和諾德A/S的NVO Ozempic和Wegovy，比那些通過飲食和運動減肥的患者經(jīng)歷肌肉損失的速度要快得多。。

U.S. pharmacy claims data analysis reveals that only one in four patients prescribed Wegovy and Ozempic continue their treatment after two years.

U、 美國藥房索賠數(shù)據(jù)分析顯示，處方Wegovy和Ozempic的患者中只有四分之一在兩年后繼續(xù)治療。

In the Financial Times report, Yancopoulos emphasized that patients often regain weight but with a higher fat-to-muscle ratio, which Yancopoulos described as “adding insult to injury.”

在《金融時報》的報告中，Yancopoulos強調(diào)，患者通常會恢復體重，但脂肪與肌肉的比例更高，Yancopoulos將其描述為“對傷害的侮辱”

He expressed concerns that GLP-1s may trigger body composition changes that could lead to more harm than benefit in the long run when used in the real world.

他表示擔心GLP-1可能會引發(fā)身體成分的變化，從長遠來看，在現(xiàn)實世界中使用GLP-1可能會導致弊大于利。

A study published in the Journal of the American Medical Association (JAMA) revealed that patients, on average, achieved only a 3.7% weight reduction after one year on the drugs—lower than the results reported in controlled trials.

發(fā)表在《美國醫(yī)學會雜志》（JAMA）上的一項研究顯示，服用藥物一年后，患者平均體重減輕了3.7%，低于對照試驗報告的結果。

Regeneron is researching muscle-preserving treatments to pair with these weight-loss medications.

Regeneron正在研究肌肉保護療法，以與這些減肥藥物搭配使用。

Regeneron is conducting a Phase 2 trial for trevogrumab, which blocks the hormone myostatin to promote muscle growth, in combination with Wegovy (semaglutide).

Regeneron正在進行trevogrumab的2期試驗，該試驗與Wegovy（semaglutide）聯(lián)合使用，可阻斷激素肌肉生長抑制素促進肌肉生長。

Topline results are expected in the second half of 2025.

。

In June, Regeneron released multiple ascending dose data from a Phase 1 study evaluating garetosmab (anti-activin A) and trevogrumab on body composition in healthy volunteers (n=34).

6月，Regeneron發(fā)布了一項1期研究的多個遞增劑量數(shù)據(jù)，該研究評估了garetosmab（抗激活素a）和trevogrumab對健康志愿者（n=34）身體成分的影響。

The data demonstrated that combination therapy led to greater-than-additive increases in lean mass while decreasing fat mass in healthy participants.

數(shù)據(jù)表明，聯(lián)合治療導致健康參與者的瘦體重增加超過加和，同時減少脂肪量。

In 2023, Eli Lilly And Co LLY acquired Versanis Bio for up to $1.925 billion in cash, bolstering its product profile of obesity-curbing drugs.

2023年，禮來公司（Eli Lilly）和LLY公司（Co-LLY）以高達19.25億美元的現(xiàn)金收購了Versanis Bio，從而鞏固了其減肥藥物的產(chǎn)品形象。

Eli Lilly said bimagrumab can reduce fat mass while preserving muscle mass for people with obesity and obesity-related complications.

禮來說，比馬單抗可以減少肥胖和肥胖相關并發(fā)癥患者的脂肪量，同時保持肌肉質(zhì)量。

According to FT, Yancopoulos hinted that Regeneron is considering entering the GLP-1 space by developing its drug version despite the concern. However, he remains cautious, stating that GLP-1s may not be the ultimate solution to metabolic disease.

據(jù)英國《金融時報》報道，Yancopoulos暗示，盡管存在擔憂，Regeneron仍在考慮通過開發(fā)其藥物版本進入GLP-1領域。然而，他仍然保持謹慎，指出GLP-1s可能不是代謝疾病的最終解決方案。

Price Action: REGN stock is down 0.23% tot $1,010.51 at the last check on Monday.

價格走勢：瑞金股價下跌0.23%，至周一最后一次檢查時的1010.51美元。

Taiwan Semiconductor Strengthens Europe’s Semiconductor Base.

臺灣半導體鞏固了歐洲的半導體基礎。

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.Market News and Data brought to you by Benzinga APIs? 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

該內(nèi)容部分是在AI工具的幫助下制作的，并由Benzinga編輯審閱和發(fā)布。Benzinga API為您帶來的市場新聞和數(shù)據(jù)?2024 Benzinga.com。Benzinga不提供投資建議。保留所有權利。

相關知識

醫(yī)藥公司警告：若不解決肌肉流失問題 “減肥神藥”可能弊大于利
美食品飲料等行業(yè)將迎巨變？馬斯克“站臺”的新型減肥藥風靡，沃爾瑪高管：“嗑藥”的消費者在食物上的消費有所降低
減肥藥的隱憂：肌肉萎縮的健康風險
吃藥抑制食欲，新型減肥藥風靡美國
制藥公司展開新藥研發(fā)大戰(zhàn) 或可降低心臟病風險
科學網(wǎng)—健康記錄顯示，流行的減肥藥與自殺念頭之間沒有聯(lián)系
減肥藥沖擊食品需求，沃爾瑪：“嗑藥”顧客吃的越來越少 恐沖擊食品業(yè)
諾和諾德減肥藥Wegovy在中國獲批，但公司承諾在短缺的情況下優(yōu)先考慮既有患者
減脂不減肌！這些新一代減肥療法能成為重磅藥物嗎？
是是非非“減肥神藥”，登《科學》2023年度十大科學突破

網(wǎng)址: Regeneron首席執(zhí)行官表示，Ozempic等流行減肥藥物存在健康風險，該公司表示，其肥胖藥物的目標是保護肌肉 http://m.u1s5d6.cn/newsview591520.html